These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Controlled therapeutic trial in IgA glomerulonephritis].
    Author: Belovezhdov N, Robeva R.
    Journal: Vutr Boles; 1982; 21(3):49-53. PubMed ID: 7051564.
    Abstract:
    A controlled therapeutic study was carried out on 38 patients with IgA glomerulonephritis. According to the data from the light microscopy, 15 patients were with minimum histological deviations, 21 patients--with focal-segmental glomerulonephritis, and 2 patients--with diffuse. The patients with the minimum histological deviations and focal-segmental glomerulonephritis were grouped into three groups. The first group of 13 patients was treated with indomethacin, 75 mg daily in the course of 8.5 months on the average (6-13 months). The second group of 5 patients was treated with levamisole--3 days with 150 mg daily--two times a month, in the course of 14 months on the average (6.5-30 months). The control group, without any treatment, covered 13 patients. There were no discrepancies in the clinical manifestations, laboratory data and renal function among the patients from the three groups. In an additional group of 7 patients with focal-segmental and diffuse mesangioproliferative glomerulonephritis, five of them with renal insufficiency, a combined immuno-suppressive and anticoagulant treatment with azathioprin, heparin and acenocoumarol was carried out in the course of 15 months on the average (6-35 months). Indomethacin and levamisole treatment had no effect on the clinical manifestations and evolution of the disease. The combined immuno-suppressive and anticoagulant treatment had also no effect on the progress in the terminal renal insufficiency.
    [Abstract] [Full Text] [Related] [New Search]